Form 4: Timothy A. Springer Reports Significant Stock Purchases in Cartesian Therapeutics, Inc.

Director and 10% owner Timothy A. Springer reports purchasing shares of Cartesian Therapeutics (RNAC) between April 9th and April 11th, 2025, increasing both direct and indirect holdings.

Summary

• Timothy A. Springer, a director and 10% owner of Cartesian Therapeutics, Inc. (RNAC), filed a Form 4 detailing changes in beneficial ownership.
• Between April 9th and April 11th, 2025, Springer purchased common stock in multiple transactions at varying prices.
• Direct purchases increased his holdings by thousands of shares at prices ranging from approximately $9.43 to $10.92 per share.
• Indirect purchases, through TAS Partners LLC, also increased his holdings.
• The weighted average prices for these purchases are disclosed, with Springer offering to provide detailed price breakdowns upon request.
• Following these transactions, Springer directly owns over 8.6 million shares and indirectly owns over 620,000 shares through TAS Partners LLC, and an additional 330,695 shares are held by his wife.

Sentiment

Score: 7

Explanation: Insider buying is generally viewed as a positive signal, suggesting confidence in the company's prospects. However, without additional context, it's difficult to gauge the full impact. The large number of shares already owned by Springer tempers the positive sentiment slightly.

Positives

• A director and significant shareholder increasing their stake in the company can be seen as a positive signal.
• The purchases demonstrate confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, allowing investors to gauge management's sentiment and confidence in the company's performance.

Stakeholder Impact

• Shareholders may view the insider buying as a positive signal.
• The increased holdings by a major shareholder could potentially influence corporate decisions.

Key Dates

Keywords

Form 4, Beneficial Ownership, Stock Purchases, Cartesian Therapeutics, RNAC, Springer, TAS Partners LLC, Director, 10% Owner